Ricardo Garcia: Dovitinib has received Orphan Drug Designation (ODD) from the FDA for osteosarcoma.
Ricardo Garcia, CEO and founder of Oncoheroes Biosciences, posted on his LinkedIn page:
“Here we go again! Just a few days ago, we were thrilled to share the FDA’s green light to allow us to proceed with the clinical trials of two of our potential drugs for pediatric oncology, Volasertib and Dovitinib. Today, we have even more reasons to celebrate as we proudly announce a significant achievement: Dovitinib has received Orphan Drug Designation (ODD) from the FDA for its promising role in combating osteosarcoma, a recognition previously bestowed upon Volasertib.
Our tireless commitment to pioneering groundbreaking treatments is yielding remarkable results. Both Volasertib and Dovitinib have also earned Rare Pediatric Disease Designation from the FDA, an honor that extends their eligibility for Priority Review Vouchers (PRV). For those who may not be familiar with PRVs, they are invaluable incentives for the development of pediatric cancer drugs.
Our journey is far from over, and we are immensely grateful for everyone supporting our mission in one way or another.
Onwards!”
Source: Ricardo Garcia/LinkedIn
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows